IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study.

已完结 10 由 1 发布于 2026/1/26 10:48:25

DOI:10.1016/s2352-3026(25)00253-4
作者：Qianwen Xu,Yugang Guo,Min Gao,Lei Xue,Hui Xu,Hui Li,Xuhan Zhang,Chongling Liu,Youjia Li,Qian Chen,Jingjing Ren,Karthik Sathiyanadan,Yongxian Hu,Li Tang,He Huang,Xingbing Wang
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BACKGROUND Although chimeric antigen receptor (CAR) T-cell therapy has improved clinical outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia, treatment re

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SageEXPRESS: From Owning to Connecting: Understanding and Leveraging the Effect of Internet Meme Marketing